SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Weight Watchers International, Inc. of Class Action Lawsuit and Upcoming Deadline -- WTW

NEW YORK, April 11, 2014 (GLOBE NEWSWIRE) -- Pomerantz LLP announces the filing of a class action lawsuit against Weight Watchers International, Inc. ("Weight Watchers" or the "Company") (NYSE: WTW ) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 14-cv-2216, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Weight Watchers between February 14, 2012 and October 30, 2013, both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Weight Watchers securities during the Class Period, you have until May 20, 2014, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Weight Watchers provides weight management services in North America, the United Kingdom, Continental Europe, Australia, New Zealand, and internationally. 

The Complaint alleges that the defendants issued materially false and misleading statements regarding the Company's financial performance and future prospects and failed to disclose adverse facts, including that: (a) Weight Watchers was experiencing execution issues which were causing it to miss its internally forecasted financial plan; (b) Weight Watchers was experiencing a significant drop in its North America and United Kingdom meeting attendance figures; and (c) Weight Watchers was facing increased competition from free weight-loss apps and its enrollment was being negatively impacted. As a result of the foregoing, defendants lacked a reasonable basis for their positive statements about Weight Watchers, its revenues, earnings, prospects and business.

On February 14, 2012, Weight Watchers announced results for its fourth quarter and full-year 2011, and provided full-year 2012 earnings guidance. In addition, Weight Watchers announced that it planned to launch a "modified Dutch auction" tender offer the following week for up to $720 million of its common stock with a price range between $72 and $83 per share, and that it separately had agreed to purchase shares held by its controlling shareholder, Artal Group, S.A. ("Artal"), at the same price paid in the tender offer. The tender offer closed on March 22, 2012.   Earlier that month,  defendants David Kirchhoff and Ann Sardini exercised large quantities of options in the $42-$53 per share range, and sold large quantities of Weight Watchers shares on the open market for $80-$82 per share. On March 22, 2012, they also tendered shares to the Company for $82 per share. Combined, Kirchhoff and Sardini received gross proceeds on shares sold of approximately $11 million.

On April 9, 2012, per the terms of the tender offer, Artal sold 9.5 million shares at $82 per share, for total proceeds of $779 million.

On May 2, 2012, the Company announced its results for its 2012 first quarter - the period ended March 31, 2012, just nine days after the tender offer closed - and revised downward its full-year 2012 earnings guidance that it had previously provided on February 14, 2012.   Defendant Kirchhoff attributed the disappointing results to "execution issues."

On this news, the price of Weight Watchers common stock fell 18%, from $76.01 per share on May 2, 2012, to close at $62.29 per share on May 3, 2012.

On February 13, 2013, Weight Watchers issued a press release announcing its fourth quarter 2012 financial results and provided disappointing full-year fiscal 2013 earnings guidance that widely missed Thomson Reuters' consensus estimate.

On this news, the price of Weight Watchers common stock plummeted 17%, from $54.11 per share on February 13, 2013, to close at $44.91 per share on February 14, 2013.

On October 30, 2013, Weight Watchers announced its results for the third quarter of fiscal 2013, disclosing that year-over-year quarterly revenues had declined 8.5%, and that quarterly net income had decreased by 10.5% and fully-diluted quarterly earnings per share had declined 11.2% from the same period the prior year. In addition, Weight Watchers announced that it had indefinitely suspended its dividend, which it had paid regularly since 2006.

On this news, Weight Watchers stock fell $7.81 per share, or over 19%, from a close of $39.92 per share on October 30, 2013, to close at $32.11 per share on October 31, 2013.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

Robert S. Willoughby Pomerantz LLP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading